Encephalitis (HSV-1)
Overview
Plain-Language Overview
Encephalitis (HSV-1) is a serious infection that affects the brain, caused by the herpes simplex virus type 1. This condition leads to inflammation of the brain tissue, which can cause symptoms like fever, headache, confusion, and sometimes seizures. The virus usually reaches the brain through nerve pathways and causes damage to areas responsible for memory and behavior. Because the brain controls many vital functions, this infection can significantly impact a person's health and ability to think clearly. Early recognition is important due to the potential for severe complications.
Clinical Definition
Encephalitis (HSV-1) is an acute inflammation of the brain parenchyma caused by reactivation or primary infection with herpes simplex virus type 1, a neurotropic DNA virus. The infection predominantly affects the temporal and frontal lobes, leading to necrotizing inflammation and neuronal death. It is the most common cause of sporadic fatal encephalitis in adults and is characterized by rapid onset of fever, altered mental status, focal neurological deficits, and seizures. The pathogenesis involves viral replication within neurons and subsequent immune-mediated damage. Early diagnosis and treatment are critical to reduce morbidity and mortality associated with this condition.
Inciting Event
Reactivation of latent HSV-1 from sensory ganglia is the primary trigger.
Primary HSV-1 infection can rarely cause encephalitis, especially in children.
Stress, fever, or immunosuppression may precipitate viral reactivation.
Latency Period
Symptoms typically develop within days to 1 week after viral reactivation.
There is often a prodromal phase of nonspecific symptoms lasting 1-3 days before neurological signs.
Diagnostic Delay
Early symptoms mimic common viral illnesses or psychiatric disorders, leading to misdiagnosis.
Lack of early brain imaging or lumbar puncture delays diagnosis.
Failure to consider HSV-1 encephalitis in patients with acute altered mental status causes delay.
Clinical Presentation
Signs & Symptoms
Acute onset fever and headache
Confusion progressing to decreased consciousness
Focal seizures often involving the face or arm
Behavioral changes including irritability or hallucinations
Dysphasia or other language disturbances
History of Present Illness
Initial presentation includes fever, headache, and malaise followed by rapid onset of confusion and focal neurological deficits.
Seizures and altered consciousness develop within days of symptom onset.
Patients often report prodromal flu-like symptoms before neurological decline.
Past Medical History
History of oral herpes (HSV-1) infections may be present.
Immunosuppressive conditions or therapies increase risk and severity.
Prior neurological disorders or head trauma may predispose to encephalitis.
Family History
There is no well-established familial predisposition to HSV-1 encephalitis.
Rare cases of inborn errors of immunity affecting antiviral responses may cluster in families.
Family history of herpes simplex virus infections may be noted but is not predictive.
Physical Exam Findings
Fever and altered mental status including confusion or lethargy
Focal neurological deficits such as aphasia or hemiparesis
Neck stiffness indicating meningeal irritation
Seizures often focal or generalized
Papilledema may be present if increased intracranial pressure develops
Diagnostic Workup
Diagnostic Criteria
Diagnosis of herpes simplex encephalitis relies on clinical presentation with acute onset fever, altered consciousness, and focal neurological signs. Brain MRI typically shows hyperintense lesions in the temporal lobes on T2-weighted and FLAIR sequences. Cerebrospinal fluid analysis reveals lymphocytic pleocytosis and elevated protein. The definitive diagnosis is confirmed by detection of HSV-1 DNA via PCR in the cerebrospinal fluid, which is the gold standard test.
Pathophysiology
Key Mechanisms
Reactivation of latent HSV-1 in the trigeminal ganglia leads to viral spread to the temporal lobe.
Direct viral cytotoxicity causes necrotizing inflammation primarily in the temporal and frontal lobes.
Host immune response contributes to neuronal damage and cerebral edema.
Disruption of the blood-brain barrier facilitates viral invasion and inflammatory cell infiltration.
| Involvement | Details |
|---|---|
| Organs | Brain is the primary organ affected, with HSV-1 causing focal necrotizing encephalitis predominantly in the temporal lobes. |
Cerebrospinal fluid reflects CNS inflammation and viral infection, aiding diagnosis through PCR detection of HSV-1 DNA. | |
| Tissues | Temporal lobe tissue is characteristically involved in HSV-1 encephalitis, showing edema, necrosis, and hemorrhage. |
Brain parenchyma undergoes inflammation and necrosis leading to neurological deficits. | |
| Cells | Neurons are the primary cells infected by HSV-1, leading to neuronal necrosis and dysfunction. |
Microglia act as resident immune cells in the CNS, mediating inflammatory responses during encephalitis. | |
T lymphocytes infiltrate the brain to mount an adaptive immune response against HSV-1 infection. | |
| Chemical Mediators | Interleukin-6 (IL-6) is elevated in cerebrospinal fluid and contributes to CNS inflammation in HSV-1 encephalitis. |
Tumor necrosis factor-alpha (TNF-α) promotes inflammatory damage and blood-brain barrier disruption. | |
Interferon-gamma (IFN-γ) enhances antiviral immune responses against HSV-1 in the brain. |
Treatments
Pharmacological Treatments
Acyclovir
- Mechanism:
Inhibits viral DNA polymerase after phosphorylation by viral thymidine kinase, preventing HSV-1 DNA replication.
- Side effects:
Nephrotoxicity
Neurotoxicity
Gastrointestinal upset
- Clinical role:
First-line
Non-pharmacological Treatments
Supportive care including airway management and seizure control is essential in managing HSV-1 encephalitis.
Monitoring and managing intracranial pressure may be necessary to prevent brain herniation.
Rehabilitation therapies such as physical and cognitive therapy aid recovery from neurological deficits.
Prevention
Pharmacological Prevention
Acyclovir prophylaxis in immunocompromised patients with prior HSV infection
No routine vaccine available for HSV-1 encephalitis prevention
Prompt antiviral treatment reduces risk of severe sequelae but does not prevent initial infection
Non-pharmacological Prevention
Avoidance of direct contact with active HSV lesions to reduce transmission
Good hand hygiene to prevent viral spread
Screening and management of immunosuppression to reduce risk
Education on early recognition of HSV symptoms for timely treatment
Use of protective barriers during oral contact to limit HSV-1 exposure
Outcome & Complications
Complications
Increased intracranial pressure leading to herniation
Status epilepticus from uncontrolled seizures
Cerebral edema causing neurological deterioration
Secondary bacterial infections such as pneumonia
Permanent neurological deficits including cognitive impairment
| Short-term Sequelae | Long-term Sequelae |
|---|---|
|
|
Differential Diagnoses
Encephalitis (HSV-1) versus Herpes Simplex Virus Type 2 (HSV-2) Encephalitis
Encephalitis (HSV-1) | Herpes Simplex Virus Type 2 (HSV-2) Encephalitis |
|---|---|
Encephalitis caused by HSV-1, most common cause of sporadic viral encephalitis in adults | Encephalitis caused by HSV-2, more common in neonates and immunocompromised adults |
Predominant involvement of temporal lobes and orbitofrontal cortex | More frequent involvement of brainstem and spinal cord |
Typically presents with acute onset of focal temporal lobe neurological deficits and altered mental status | Often presents with meningitis symptoms and less focal temporal lobe signs |
Encephalitis (HSV-1) versus Autoimmune Limbic Encephalitis
Encephalitis (HSV-1) | Autoimmune Limbic Encephalitis |
|---|---|
Positive HSV-1 DNA PCR in CSF | Presence of autoantibodies such as anti-NMDA receptor or anti-LGI1 antibodies in CSF or serum |
Acute onset with fever, headache, and rapid progression over days | Subacute onset with progressive memory loss, psychiatric symptoms, and seizures over weeks |
Unilateral or asymmetric temporal lobe involvement often with hemorrhagic necrosis | Bilateral symmetric involvement of medial temporal lobes without hemorrhage |
Encephalitis (HSV-1) versus Cerebral Toxoplasmosis
Encephalitis (HSV-1) | Cerebral Toxoplasmosis |
|---|---|
Occurs in immunocompetent or immunocompromised patients without specific immunosuppression | History of immunosuppression or HIV infection with CD4 count <100 cells/mm³ |
Temporal lobe edema and hemorrhagic necrosis without multiple ring-enhancing lesions | Multiple ring-enhancing lesions with surrounding edema, often in basal ganglia |
Positive HSV-1 PCR in CSF | Positive serum or CSF toxoplasma IgG antibodies and response to anti-toxoplasma therapy |
Encephalitis (HSV-1) versus Bacterial Meningoencephalitis
Encephalitis (HSV-1) | Bacterial Meningoencephalitis |
|---|---|
CSF shows lymphocytic pleocytosis, normal or mildly decreased glucose, and elevated protein | CSF shows neutrophilic pleocytosis, low glucose, and high protein |
Subacute onset with fever, altered mental status, and focal temporal lobe signs | Rapid onset with high fever, neck stiffness, and purulent CSF |
Requires intravenous acyclovir for clinical improvement | Improvement with empiric broad-spectrum antibiotics |
Encephalitis (HSV-1) versus Progressive Multifocal Leukoencephalopathy (PML)
Encephalitis (HSV-1) | Progressive Multifocal Leukoencephalopathy (PML) |
|---|---|
Can occur in immunocompetent or mildly immunocompromised patients | Occurs in severely immunocompromised patients, especially with HIV/AIDS or immunosuppressive therapy |
Temporal lobe lesions with hemorrhagic necrosis and contrast enhancement | Multifocal, non-enhancing white matter lesions without mass effect or hemorrhage |
HSV-1 DNA detected in CSF by PCR | JC virus DNA detected in CSF by PCR |